Pharmaceutical

Automated Technology Enhances Dairy Farm Management

Builds on Strong MSD Animal Health Commitment to New Zealand Farmers

Complements Broad MSD Animal Health Portfolio of Medicines, Vaccines and Technology Solutions

MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced its intention to acquire the assets of LIC Automation Ltd. ("LICA"), from New Zealand-based, farmer-owned cooperative Livestock Improvement Corporation Ltd. ("LIC"). LICA is a leader in automation and technology for the dairy industry. Specific terms of the agreement were not disclosed.

LICA, a privately held company in New Zealand, manufactures and supplies specialised, integrated herd management systems and milk-testing sensors for the dairy industry. Farm productivity has become increasingly important on the dairy farm. LICA's automated offerings including Protrack technology solutions, enables dairy farmers to gather precise information on the health and milking habits of dairy cows, which supports their efforts in herd management, real-time milk analysis, animal evaluation and reproductive health and wellness. LICA products are available in New Zealand and in selected European markets.

"We are pleased to take this step forward with the acquisition of LICA technology, as we continue to broaden our portfolio with complementary products and technologies to advance animal well-being and outcomes for our customers," said Rick DeLuca, president, MSD Animal Health. "Our portfolio of enhanced dairy farm management and livestock intelligence solutions for the dairy industry help address the evolving customer needs of dairy farmers and strengthen our leadership in shaping the future of animal health."

"We are excited to add LICA's products to our existing veterinary medicines, vaccines and health management solutions and services, as well as Allflex Livestock Intelligence's digitally connected identification, traceability and monitoring products to benefit farmers and veterinarians," said Pauline Calvert, Livestock Business Unit lead, MSD Animal Health, New Zealand. "MSD Animal Health has a substantial footprint in New Zealand as a leading partner in the agricultural community. The solutions we offer build upon our strong presence in New Zealand, which includes manufacturing facilities at Palmerston North (Allflex Livestock Intelligence, a business unit within MSD Animal Health), Upper Hutt (animal health vaccines) and now Hamilton (LICA milking intelligence and automation). We are exceptionally proud of our continuous commitment and investment to advance animal health and well-being for our unique pastoral-based farming systems in Aotearoa (New Zealand), that supports the efforts of our farmers' in their day-to-day operations today and into the future. We look forward to continuing to expand our world-class animal health solutions both locally and globally."

LICA's product portfolio joins Allflex Livestock Intelligence, the leading New Zealand livestock intelligence business. Allflex Livestock Intelligence is a complementary business that specialises in identification and monitoring technology that delivers real-time, actionable data and insights to help improve livestock management.

"We are pleased that MSD Animal Health has chosen to acquire this technology," said Wayne McNee, LIC chief executive. "MSD Animal Health has a reputation for investing heavily in research and development for animal health and welfare. The company has extensive scientific and technological capabilities that can take this technology to the next phase and deliver more value to farmers."

About MSD Animal Health

For 130 years, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to The Science of Healthier Animals™ , MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn and Twitter .

About LIC Automation

LICA is a subsidiary of Livestock Improvement Corporation (LIC), a New Zealand based farmer-owned co-operative and world leader in pasture-based dairy genetics and herd management. LIC exists to deliver superior genetics and technological innovation to help our shareholder sustainably farm a profitable animal.

LICA manufacturers and supplies integrated herd management systems and unique milk testing sensors for the dairy industry. Automation is an important part of farm performance and herd management, to help dairy farmers to improve prosperity and productivity. The innovative in-shed systems, known as Protrack, simplify complex jobs and improve decision making on-farm, to deliver improved herd management, animal health and welfare, real-time milk analysis, increased labour efficiency and profit. The proprietary technology identifies each cow in the milking herd from their ear tags to provide automated drafting, heat detection, body condition scoring and targeted feeding. The systems also enable real-time animal recording and review, individual cow alerts and live analysis through milk testing sensors that measure fat, protein, somatic cell counts, lactose, conductivity, and volume while a cow is being milked.

The first Protrack system was installed on a New Zealand dairy farm in 2004. Today, more than 2500 dairy farms benefit from this state-of-the-art technology. The LICA business was formed in 2015, to amalgamate the co-op's automation solutions into a single, standalone entity.

About LIC

LIC is a farmer-owned co-operative and world leader in pasture based dairy genetics and herd management. LIC exists to deliver superior genetics and technological innovation to help its shareholders sustainably farm a profitable animal.

With origins dating back to 1909, LIC has a long history of developing and delivering world-leading innovations for the dairy industry. The co-op continues to be one of the sector's biggest private investors in research and development.

Today the New Zealand-based co-op employs more than 700 permanent staff, swelling to 2000 during the spring peak dairy mating season. LIC also has offices in the United Kingdom, Ireland and Australia.

All LIC profit is returned to its farmer owners/shareholders in dividends, or reinvested for new solutions, research and development. www.lic.co.nz

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2020 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( www.sec.gov ).

MSD
Media Contact:
Jeanette Lewis
+ 1 (973) 294-0318
Jeanette.Lewis@merck.com

LICA Media Contact:
Ashleigh Sattler
+64 276171942
Ashleigh.sattler@lic.co.nz

MSD
Investor Contact:
Peter Dannenbaum
+ 1 (908) 740-1037
Peter.Dannenbaum@merck.com

News Provided by Business Wire via QuoteMedia

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

  • Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S.

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005463/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion

Potential to address the full spectrum of critical needs in the underserved sickle cell community

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

  • Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment
  • Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediately
  • Myovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE ® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. The approval is supported by one-year efficacy and safety data, including 24-week data from the Phase 3 SPIRIT 1 and SPIRIT 2 trials, which were published in The Lancet and the first 28 weeks of an open-label extension study for eligible women who completed either SPIRIT 1 or SPIRIT 2. MYFEMBREE also is approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Myovant and Pfizer will continue to jointly commercialize MYFEMBREE in the U.S. and product is available immediately.

"Endometriosis is a painful, chronic disease with limited therapies to manage symptoms," said Juan Camilo Arjona Ferreira, M.D., Chief Medical Officer of Myovant Sciences, Inc. "The new MYFEMBREE indication helps advance our mission to redefine care for women by helping address a disease with high unmet need, giving women and physicians a new meaningful treatment option to manage moderate to severe pain associated with endometriosis."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Reports Second Quarter 2022 Financial Results

Company Increases Fiscal 2022 Guidance and Raises Second Quarter Dividend

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its second quarter ended June 30, 2022. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

LYNPARZA® Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA 1/2 mutations (g BRCA m), who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® Plus LENVIMA® Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Phase 3 LEAP-002 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus LENVIMA monotherapy did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). There were trends toward improvement in OS and PFS for patients who received KEYTRUDA plus LENVIMA versus LENVIMA monotherapy; however, these results did not meet statistical significance per the pre-specified statistical plan. The median OS of the LENVIMA monotherapy arm in LEAP-002 was longer than that observed in previously reported clinical trials evaluating LENVIMA monotherapy in uHCC. The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination. Merck and Eisai plan to present these data at an upcoming medical conference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803005211/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×